HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce the new publication of an independent study reporting positive data on the accuracy and usefulness of the Company's Saliva NicAlert™ test for tobacco exposure in a family practice setting. Saliva NicAlert™ results using saliva samples tested on-site closely matched those obtained by much more expensive and complex testing technology using urine samples sent off-site to an independent reference laboratory. Importantly, Saliva NicAlert™ was able to correctly identify smokers who reported being nonsmokers but were ascertained to actually be smokers based on the reference laboratory liquid chromatography/mass spectroscopy results.
